Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients
NCT03328884
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
55
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer Metastatic
Interventions
DRUG:
Irinotecan (CPT-11) liposome
Sponsor
MedSIR